Form 4: Corcept Therapeutics Executive Gary Robb Reports Stock Transactions
SEC Form 4 Filing
Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports stock transactions including tax withholding, purchase plan acquisitions, and restricted stock awards.
Summary
- Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On March 1, 2024, 656 shares were withheld by the issuer to cover tax obligations related to vesting restricted stock units at a price of $24.06.
- On the same day, Robb acquired 697 shares through a purchase plan at $24.06 per share.
- Additionally, Robb acquired 697 shares underlying unvested restricted stock awards granted under the purchase plan at $0.00.
- Following these transactions, Robb directly owns 20,203 shares, including unvested restricted stock awards.
- Robb also indirectly owns shares through custodial accounts for his child.
- The filing indicates that a power of attorney is on file with the Commission.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is standard practice for publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of stock transactions including tax withholding, purchase plan acquisition, and restricted stock awards. |
| 03/05/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.